Avantor stock reacts as new CFO Todd Garner steps in

Avantor, Inc. stock (ISIN US05352A1007) finished the September 18, 2026 New York Stock Exchange session at USD 15.52, with a daily decline of 2.14 percent ahead of a key management change in its finance leadership as of September 21, 2026, according to RTTNews.

Management change: Todd Garner becomes CFO

Avantor, Inc., a global provider of mission-critical products and services to life sciences and advanced technology industries, has appointed Todd Garner as Executive Vice President and Chief Financial Officer, effective September 21, 2026, taking over responsibility for the company’s global finance organization including financial planning, accounting, treasury, tax, investor relations and internal audit, as reported by StockTitan on September 21, 2026.

According to GuruFocus on September 21, 2026, Garner joins Avantor from CONMED Corporation, where he previously served as Executive Vice President and Chief Financial Officer, bringing experience from the medical technology sector that may be relevant for Avantor’s portfolio.

As Fortune noted on September 21, 2026, Garner succeeds Steve Eck, who had served as interim Chief Financial Officer since June 24, 2026 and will continue as Senior Vice President and Chief Accounting Officer, implying continuity in the accounting function while finance leadership transitions.

Stock performance and earnings backdrop

Avantor stock has delivered a strong performance in 2026: based on data summarized by Zacks on September 21, 2026, the shares have gained about 35.4 percent year to date, compared with an average return of 2.1 percent for medical-sector companies, highlighting a performance gap of 33.3 percentage points in Avantor’s favor.

According to the same overview from Zacks on September 21, 2026, Avantor carries a Zacks Rank of 2 (Buy), and the consensus estimate for its full-year earnings has improved by 2.9 percent over the past 90 days, indicating that analysts have modestly raised their expectations for the company’s profitability for fiscal year 2026.

Avantor’s most recent reported quarter within the current freshness window is the second quarter of 2026, for which the company released results on July 29, 2026, as listed in the news chronology on StockTitan; while this hit references the date, it does not summarize specific revenue or earnings numbers, so these figures remain part of the broader earnings context rather than explicit current key figures in this article.

Valuation context and market data

The governance update has drawn attention to Avantor’s valuation. A recent Form 8-K filing dated September 21, 2026 and summarized by StockTitan lists Avantor’s market capitalization at approximately USD 10.50 billion as of that disclosure date, providing a scale reference for investors assessing the company relative to peers in the medical instruments and supplies industry.

In the same context, StockTitan confirms that Avantor’s common stock, with a par value of USD 0.01 per share, trades on the New York Stock Exchange under the ticker symbol AVTR, situating the stock within the US large and mid-cap equity universe accessible to global investors.

While detailed 52-week high and low levels or specific trading volumes are not explicitly enumerated in the available week-filtered sources, the combination of a USD 15.52 closing price on September 18, 2026 and a market capitalization of USD 10.50 billion as of September 21, 2026 shows that Avantor remains a mid-cap name in the medical instruments and supplies segment, with price and value metrics that investors can compare with sector averages.

Analyst view and governance implications

The incremental improvement in full-year earnings estimates, up 2.9 percent over the last 90 days for fiscal year 2026 according to Zacks on September 21, 2026, suggests that analysts are gradually factoring in a stronger earnings trajectory, even before any potential strategic changes that might follow the CFO appointment.

The governance update itself is framed as a leadership strengthening move: Investing.com reported on September 21, 2026 that Avantor’s press release describes Garner’s appointment as effective immediately, underlining his role in overseeing finance as the company pursues its strategy in life sciences and advanced technology markets.

For investors, one key question will be how Garner’s background at CONMED Corporation influences Avantor’s capital allocation, margin focus and potential acquisition or divestiture decisions, especially given the company’s outperformance versus the broader medical sector by 33.3 percentage points year to date as of September 21, 2026 per Zacks.

Avantor stock price snapshot

Avantor stock’s most recent completed reference closing price in the available week-filtered sources is USD 15.52 on the New York Stock Exchange as of September 18, 2026, with a daily decline of 2.14 percent from the prior session, according to RTTNews; this closing level serves as the price anchor for investors evaluating the impact of the September 21, 2026 CFO appointment on Avantor stock.

More news and analyses on Avantor stock